- Conditions
- Type 1 Diabetes Mellitus, Coronary Artery Disease
- Interventions
- Not listed
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Rapid Acting insulin with pre-treatment of rHuPH20, Sham injection
- Drug · Device
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- otelixizumab infusion plus physician determined standard of care, placebo infusion plus physician determined standard of care
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years to 45 Years
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 58 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Sirolimus, Tacrolimus, Mycophenolate mofetil, Mycophenolic acid
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- U.S. locations
- 3
- States / cities
- Miami, Florida • Boston, Massachusetts • St Louis, Missouri
- Conditions
- Type 1 Diabetes, Obesity
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2012
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 1 Year to 35 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Tallahassee, Florida • Philadelphia, Pennsylvania + 2 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Islet transplant, Antithymocyte globulin, Basiliximab, Lisofylline, Sirolimus, Tacrolimus
- Procedure · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 2
- States / cities
- Miami, Florida • Chicago, Illinois
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 46
- States / cities
- Little Rock, Arkansas • Concord, California • La Jolla, California + 43 more
- Conditions
- Diabetes Mellitus, Type 1, Hypoglycemia, Islet Cell Transplantation, Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes (T1D), Severe Hypoglycemia, Xenotransplantation, Hypoglycemic Episode, Islet Transplantation in Diabetes Mellitus Type 1, Glucose Metabolism Disorders (Including Diabetes Mellitus), Immune System Diseases, Autoimmune Diseases, Metabolic Disease
- Interventions
- OPF-310
- Combination Product
- Lead sponsor
- Otsuka Pharmaceutical Factory, Inc.
- Industry
- Eligibility
- 35 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Type 1 Diabetes
- Interventions
- Semaglutide (Rybelsus®), Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes in Adolescence, Type 1 Diabetes in Children, Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Type 1 Diabetes Patients, Type 1 Diabetes Mellitis
- Interventions
- CNP-103, Placebo
- Drug
- Lead sponsor
- COUR Pharmaceutical Development Company, Inc.
- Industry
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 30
- States / cities
- Tucson, Arizona • San Diego, California • Walnut Creek, California + 26 more
- Conditions
- Type 1 Diabetes Mellitus, T1DM, T1D
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 8 Years to 35 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 12
- States / cities
- San Francisco, California • Stanford, California • Aurora, Colorado + 9 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Pioglitazone 45 mg, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes Mellitus
- Interventions
- AC2993 (exenatide), daclizumab (immunosuppressive)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diabetic Kidney Disease
- Interventions
- INV-202, Placebo
- Drug
- Lead sponsor
- Inversago Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 23
- States / cities
- Garden Grove, California • Pomona, California • Salinas, California + 19 more
- Conditions
- Type 1 Diabetes
- Interventions
- Pramlintide and glucagon
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- INGAP Peptide, Placebo
- Drug
- Lead sponsor
- Exsulin Corporation
- Industry
- Eligibility
- 19 Years to 60 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Diabetes Mellitus, Diabetes Type 1
- Interventions
- ACZ885, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 35 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Aralast NP, Placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 8 Years to 35 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 15
- States / cities
- La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 10 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Continuous glucose monitor, Home blood glucose monitor
- Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 4 Years to 9 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- Stanford, California • New Haven, Connecticut • Jacksonville, Florida + 2 more
- Conditions
- Type 1 Diabetes Mellitus (T1DM), High Level of Sugar (Glucose) in the Blood
- Interventions
- Sotagliflozin, Placebo
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 33
- States / cities
- Concord, California • Escondido, California • La Jolla, California + 30 more
- Conditions
- Hypoglycemia, Diabetes Mellitus, Type 1
- Interventions
- dasiglucagon, GlucaGen
- Drug
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Meridian, Idaho
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Placebo Oral Tablet, Fluoxetine, DHEA, Fluoxetine and DHEA
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- CareSens Air 3 primary insertion, CareSens Air 3 secondary insertion
- Device
- Lead sponsor
- i-SENS, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 4
- States / cities
- Escondido, California • Walnut Creek, California • Atlanta, Georgia + 1 more